Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The evidence that motivated an independent review of breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Synchronous bilateral breast cancer: a nationwide study on histopathology and etiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • International Immuno-Oncology Biomarker Working Group
Vis graf over relationer

Stromal tumor-infiltrating lymphocytes (sTILs) are important prognostic and predictive biomarkers in triple-negative (TNBC) and HER2-positive breast cancer. Incorporating sTILs into clinical practice necessitates reproducible assessment. Previously developed standardized scoring guidelines have been widely embraced by the clinical and research communities. We evaluated sources of variability in sTIL assessment by pathologists in three previous sTIL ring studies. We identify common challenges and evaluate impact of discrepancies on outcome estimates in early TNBC using a newly-developed prognostic tool. Discordant sTIL assessment is driven by heterogeneity in lymphocyte distribution. Additional factors include: technical slide-related issues; scoring outside the tumor boundary; tumors with minimal assessable stroma; including lymphocytes associated with other structures; and including other inflammatory cells. Small variations in sTIL assessment modestly alter risk estimation in early TNBC but have the potential to affect treatment selection if cutpoints are employed. Scoring and averaging multiple areas, as well as use of reference images, improve consistency of sTIL evaluation. Moreover, to assist in avoiding the pitfalls identified in this analysis, we developed an educational resource available at www.tilsinbreastcancer.org/pitfalls .

OriginalsprogEngelsk
TidsskriftCurrent Medical Literature. Breast Cancer
Vol/bind6
Udgave nummer1
Sider (fra-til)17
ISSN2374-4677
DOI
StatusUdgivet - 12 maj 2020

ID: 62371180